Skip to main content
Top
Published in: Archives of Dermatological Research 6/2023

Open Access 01-03-2023 | Melasma | STUDY PROTOCOL

Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study

Authors: Israa Gomaa Abd Elraouf, Zakaria Mahran Obaid, Ibrahim Fouda

Published in: Archives of Dermatological Research | Issue 6/2023

Login to get access

Abstract

Millions of people throughout the world suffer from the acquired condition of hyperpigmentation known as melasma. Melasma is characterized by symmetrically oriented hyperpigmented macules and patches. Many treatment options are available with variable degrees of efficacy and tolerability. The aim of the work was to evaluate and compare the effectiveness and safety of intradermal tranexamic acid (TXA) versus intradermal platelet-rich plasma (PRP) in the treatment of various types of melasma. The current split-face prospective study included 40 cases with melasma. Tranexamic acid (TXA) was injected intradermally into the right side of the face by using a concentration of 4 mg/ml, while platelet-rich plasma (PRP) was injected intradermally into the left side. In both sides, a total of three sessions of treatment were provided, once every 4 weeks. Digital photographs were taken before each treatment session and 3 months after the last session. The modified melasma area severity index (mMASI) grading system and dermoscopy were used to assess the improvement in the condition. The disease severity and percentage of improvement were assessed by mMASI score before and after therapy across both sides of the face. along with determining the degree of satisfaction and side effects among the included cases. The mean mMASI score before therapy in the TXA side was 4.59 ± 2.87, while in the PRP side, the mean mMASI score before therapy was 4.72 ± 2.72 with no statistically significant difference between the two sides (p = 0.841). After 3 months of treatment, the mean mMASI score in the TXA-treated side was 2.49 ± 1.58 with a mean percentage of decrease of 45.67 ± 8.10%, while in the PRP side, the mean mMASI score after treatment was 2.17 ± 1.41 with a mean percentage of decrease of 53.66 ± 11.27%. There was a high statistically significant decrease in the mMASI score after treatment on both sides (p < 0.001); however, the percentage of score reduction in the PRP side compared to the TXA side was statistically higher. Intradermal injection with PRP revealed higher efficacy in the treatment of melasma as compared to TXA injection with no significant difference regarding the associated side effects.
Literature
1.
go back to reference Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M (2018) Oral tranexamic acid for the treatment of melasma: a review. Dermatol Surg 44(6):814–825CrossRefPubMed Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M (2018) Oral tranexamic acid for the treatment of melasma: a review. Dermatol Surg 44(6):814–825CrossRefPubMed
2.
go back to reference Sarkar R, Ailawadi P, Garg S (2018) Melasma in men: a review of clinical, etiological, and management issues. J Clin Aesthetic Dermatolo 11(2):53 Sarkar R, Ailawadi P, Garg S (2018) Melasma in men: a review of clinical, etiological, and management issues. J Clin Aesthetic Dermatolo 11(2):53
3.
go back to reference Zhang L, Tan W-Q, Fang Q-Q, Zhao W-Y, Zhao Q-M, Gao J, et al. (2018) Tranexamic acid for adults with melasma: a systematic review and meta-analysis. BioMed Research International. Zhang L, Tan W-Q, Fang Q-Q, Zhao W-Y, Zhao Q-M, Gao J, et al. (2018) Tranexamic acid for adults with melasma: a systematic review and meta-analysis. BioMed Research International.
4.
go back to reference Sarkar R, Gokhale N, Godse K, Ailawadi P, Arya L, Sarma N et al (2017) Medical management of melasma: a review with consensus recommendations by Indian pigmentary expert group. Indian J Dermatol 62(6):558PubMedCentralPubMed Sarkar R, Gokhale N, Godse K, Ailawadi P, Arya L, Sarma N et al (2017) Medical management of melasma: a review with consensus recommendations by Indian pigmentary expert group. Indian J Dermatol 62(6):558PubMedCentralPubMed
5.
go back to reference Nishida, Takeshi et al. (2017) “Tranexamic acid and trauma-induced coagulopathy.” Journal of intensive care 55 (1) Nishida, Takeshi et al. (2017) “Tranexamic acid and trauma-induced coagulopathy.” Journal of intensive care 55 (1)
6.
go back to reference Sheu SL (2018) Treatment of melasma using tranexamic acid: what’s known and what’s next. Cutis 101(2):E7–E8PubMed Sheu SL (2018) Treatment of melasma using tranexamic acid: what’s known and what’s next. Cutis 101(2):E7–E8PubMed
7.
go back to reference Wang H-L, Avila G (2013) Platelet rich plasma: myth or reality? Eur J Dentistry 7(01):192–194 Wang H-L, Avila G (2013) Platelet rich plasma: myth or reality? Eur J Dentistry 7(01):192–194
8.
go back to reference Dhurat R, Sukesh MS (2014) Principles and methods of preparation of platelet-rich plasma: a review and author’s perspective. J Cutan Aesthet Surg 7(4):189CrossRefPubMedCentralPubMed Dhurat R, Sukesh MS (2014) Principles and methods of preparation of platelet-rich plasma: a review and author’s perspective. J Cutan Aesthet Surg 7(4):189CrossRefPubMedCentralPubMed
9.
go back to reference Sarkar R, Bansal A, Ailawadi P (2020) Future therapies in melasma: What lies ahead? Indian J Dermatol Venereol Leprol 86:8–17CrossRefPubMed Sarkar R, Bansal A, Ailawadi P (2020) Future therapies in melasma: What lies ahead? Indian J Dermatol Venereol Leprol 86:8–17CrossRefPubMed
10.
11.
go back to reference Konda D, Thappa DM (2013) Mesotherapy what is new? Indian J Dermatol Venereol Leprol 79(1):127–34CrossRefPubMed Konda D, Thappa DM (2013) Mesotherapy what is new? Indian J Dermatol Venereol Leprol 79(1):127–34CrossRefPubMed
12.
go back to reference Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, Park YM (2006) Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg 32(5):626–631PubMed Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, Park YM (2006) Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg 32(5):626–631PubMed
13.
go back to reference Cayırlı M, Calışkan E, Açıkgöz G, Erbil AH, Ertürk G (2014) Regression of melasma with platelet-rich plasma treatment. Ann Dermatol 26(3):401–402CrossRefPubMedCentralPubMed Cayırlı M, Calışkan E, Açıkgöz G, Erbil AH, Ertürk G (2014) Regression of melasma with platelet-rich plasma treatment. Ann Dermatol 26(3):401–402CrossRefPubMedCentralPubMed
14.
go back to reference FawzyEwaiss M, Mohamed El-Mohsen AE-R, Mahmoud El-Rewiny E (2021) Evaluation of intradermal tranxemic acid injection in treatment of melasma. Al-Azhar Medical J 50(1):655–72CrossRef FawzyEwaiss M, Mohamed El-Mohsen AE-R, Mahmoud El-Rewiny E (2021) Evaluation of intradermal tranxemic acid injection in treatment of melasma. Al-Azhar Medical J 50(1):655–72CrossRef
15.
go back to reference Serra M, Bohnert K, Narda M, Granger C, Sadick N (2018) Brightening and improvement of facial skin quality in healthy female subjects with moderate hyperpigmentation or dark spots and moderate facial aging. J Drugs Dermatology: JDD 17(12):1310–1315 Serra M, Bohnert K, Narda M, Granger C, Sadick N (2018) Brightening and improvement of facial skin quality in healthy female subjects with moderate hyperpigmentation or dark spots and moderate facial aging. J Drugs Dermatology: JDD 17(12):1310–1315
16.
go back to reference Jin Y, Jiang W, Yao Y, Huang H, Huang J (2019) Clinical efficacy of laser combined with menstrual regulation in the treatment of female melasma: a retrospective study. Lasers Med Sci 34(6):1099–1105CrossRefPubMed Jin Y, Jiang W, Yao Y, Huang H, Huang J (2019) Clinical efficacy of laser combined with menstrual regulation in the treatment of female melasma: a retrospective study. Lasers Med Sci 34(6):1099–1105CrossRefPubMed
17.
go back to reference Mumtaz M, Chandio TH, Shahzad MK, Hanif N, Anwar S, Rafique S (2021) Comparing the efficacy of Patelet-rich Plasma (PRP) versus tranexamic Acid (4mg/mL) as intradermal Treatments of Melasma. J Coll Physicians Surg Pak 30(5):502–505PubMed Mumtaz M, Chandio TH, Shahzad MK, Hanif N, Anwar S, Rafique S (2021) Comparing the efficacy of Patelet-rich Plasma (PRP) versus tranexamic Acid (4mg/mL) as intradermal Treatments of Melasma. J Coll Physicians Surg Pak 30(5):502–505PubMed
18.
go back to reference Gharib K, Mostafa FF, Ghonemy S (2021) Therapeutic effect of Microneedling with platelet-rich plasma versus Microneedling with Tranexamic Acid for Melasma. J Clin Aesthetic Dermatol 14(8):44–48 Gharib K, Mostafa FF, Ghonemy S (2021) Therapeutic effect of Microneedling with platelet-rich plasma versus Microneedling with Tranexamic Acid for Melasma. J Clin Aesthetic Dermatol 14(8):44–48
19.
go back to reference Badran AY, Ali AU, Gomaa AS (2021) Efficacy of topical versus intradermal injection of tranexamic acid In Egyptian melasma patients: a randomised clinical trial. Australas J Dermatol 62(3):e373–e379CrossRefPubMed Badran AY, Ali AU, Gomaa AS (2021) Efficacy of topical versus intradermal injection of tranexamic acid In Egyptian melasma patients: a randomised clinical trial. Australas J Dermatol 62(3):e373–e379CrossRefPubMed
20.
go back to reference Hofny ER, Abdel-Motaleb AA, Ghazally A, Ahmed AM, Hussein MRA (2019) Platelet-rich plasma is a useful therapeutic option in melasma. J Dermatol Treat 30(4):396–401CrossRef Hofny ER, Abdel-Motaleb AA, Ghazally A, Ahmed AM, Hussein MRA (2019) Platelet-rich plasma is a useful therapeutic option in melasma. J Dermatol Treat 30(4):396–401CrossRef
21.
go back to reference Gamea MM, Kamal DA, Donia AA, Hegab DS. (2020) Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma. J DermatolTreat 1–7. Gamea MM, Kamal DA, Donia AA, Hegab DS. (2020) Comparative study between topical tranexamic acid alone versus its combination with autologous platelet rich plasma for treatment of melasma. J DermatolTreat 1–7.
22.
go back to reference Zhang C, Wu T, Shen N (2022) Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin. Pak J Med Sci 38(8):2163–2168CrossRefPubMedCentralPubMed Zhang C, Wu T, Shen N (2022) Effect of platelet-rich plasma combined with tranexamic acid in the treatment of melasma and its effect on the serum levels of vascular endothelial growth factor, endothelin-1 and melatonin. Pak J Med Sci 38(8):2163–2168CrossRefPubMedCentralPubMed
23.
go back to reference Patil NK, Bubna AK (2022) A comparative evaluation of the efficacy of intralesional tranexamic acid versus platelet rich plasma in the treatment of melasma. Dermatol Ther 35(7):e15534CrossRefPubMed Patil NK, Bubna AK (2022) A comparative evaluation of the efficacy of intralesional tranexamic acid versus platelet rich plasma in the treatment of melasma. Dermatol Ther 35(7):e15534CrossRefPubMed
24.
go back to reference Polat Y, Saraç G (2022) Comparison of clinical results of oral tranexamic acid and platelet rich plasma therapies in melasma treatment. Dermatol Ther 35(7):e15499CrossRefPubMed Polat Y, Saraç G (2022) Comparison of clinical results of oral tranexamic acid and platelet rich plasma therapies in melasma treatment. Dermatol Ther 35(7):e15499CrossRefPubMed
Metadata
Title
Intradermal injection of tranexamic acid versus platelet-rich plasma in the treatment of melasma: a split-face comparative study
Authors
Israa Gomaa Abd Elraouf
Zakaria Mahran Obaid
Ibrahim Fouda
Publication date
01-03-2023
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 6/2023
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-023-02580-y

Other articles of this Issue 6/2023

Archives of Dermatological Research 6/2023 Go to the issue